Evolus, Inc. announced that the Aesthetic Surgery Journal has published the safety and duration of effect results from the Phase 2 study of 40U Jeuveau® (prabotulinumtoxinA-xvfs) for the treatment of moderate to severe glabellar lines in adult patients. The " extra-strength" glabellar line study is a multicenter, double-blind, randomized, Phase 2 trial following 150 patients for up to 12 months or until the patient loses their correction. The study has three arms: Jeuveau® Extra- strength 40U and two active controls, BOTOX 20U and Jeuveau 20U.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.77 USD | +0.77% |
|
+7.69% | +11.78% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.78% | 731M | |
+62.66% | 841B | |
+40.42% | 625B | |
-4.37% | 360B | |
+17.16% | 327B | |
+9.87% | 300B | |
+15.66% | 242B | |
+17.90% | 227B | |
+14.86% | 174B | |
+0.45% | 162B |
- Stock Market
- Equities
- EOLS Stock
- News Evolus, Inc.
- Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau